ParaTrex 728x90 Animated 90% could you be one

Saturday, April 01, 2006

Can chelation destroy the AIDS virus?

Archives of Virology 73, 171-183 (1982)
Disintegration of Retroviruses by Chelating Agents

By V. Wunderlich and G. SydowCentral Institute for Cancer Research, Robert-Rossle-Institute,Academy of Sciences of the German Democratic, Berlin

German Democratic RepublicWith 2 figures Accepted April 2, 1982
Summary

Exposure in vitro of various mammalian retroviruses to the chelating agents EDTA or EGTA in millimolar concentrations resulted in partial disintegration of viral membranes as measured by accessibility or even release of reverse transcriptase, an internal viral protein, without any other treatment usually required.

AMong the viruses responding to chelators were mammalian type C viruses, primate type D viruses and Bovine leukemia virus. The effect was dose-dependant. The avain type C virus AMV, howeveer, was found to be not susceptible to the agents. Rauscher mouse leukemia virus treated in vitro with EDTA or EGTA showed reducedinfectivity in mice.

The results are considered as evidence for some association of divalent cations with membranes of mammalian retroviruses. The disintegrating activity of EGTA suggests that Ca2+ is an integral constituent of viruses but Mg2+ may also be involved.

These cations seem to be responsible for maintaining the integrity of retroviral membranes which, after chelation of ions, are either disrupted or become permeable for the exogenous template of reverse transcriptase. In addition, the disintegrating activity of trifluoperazine may indicate that a calmodulin-like protein occurs in retroviral membranes.

Introduction
Retroviruses contain a single stranded RNA genome and the enzyme reverse transcriptase (RT), both of which are located with the virion core. Viral particles are released by budding from the surface of infected cells and the cores are thought to acquire in this process an outer unit membrane of host cell origin.

However, little is known about the composition, architecture and topography of the viral membrane witht he possible exception of spikes and knobs protruding from the exterior of the envelope. The porphological elements are composed of predominantly glycosylated proteins encoded in the viral genome and determine many of the biological properties of the virus. (see 23 for a review). Therefore, previous investigations on the retroviral envelope have mainly been focused on those components.

The demonstration of RT activity requires the disruption of virus particles as usually performed with the aid of detergents. Our observation that the preparation of type D retroviruses in buffers containing the chelating agent ethylene-diaminetetraacetic acid (EDTA) results in considerable accessibility or even release of RT activity without the use of any detergent (32) led us to investigate more systematically the action of chelating agents on different types of retroviruses.

The results presented in this study demonstrate that susceptibility to such agents is a characteristic property of various retroviruses. Thus, the structure of retroviral membranes obviously stabilized by divalent cations may be more complex than hitherto known. Appreciation of this complexity may allow a better understanding of certain aspects of virus-cell interaction and may facilitate the future design of antiretroviral compounds.

Materials and Methods
Chemicals
EDTA (Chelaplex III, p.a.) was purchased from VEB Berlin-Chemie, Berlin-Adlershof, GDR. EGTA [ethylene glycol bis 92-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Dr. Th. Schuchardt GmbH., Munchen, FRG) was kindly provided by Dr. H. Will, Berlin. Propranol was obtained from Isis-Chemie KG< la=" 1-"> Chelation and EGTA obviously disassociated some membrane components as indicated by the appearance of RT activity in otherwise undestructed virus samples.

This effect however, was sometimes hard to reproduce possible owing to some irreversible chelator induced activation of RT, a zinc metallozyme not reactivable by Mg++ or Mn++ (25), even although either ion was additionally added to the RT reaction mixture in amounts equimolar to the chelator. (Tables not included here but an be faxed to you if you are interested in seeing them.)

Efficacy of EDTA and EGTA in Disintegrating Various Retroviruses To circumvent the problems just described, most experiments were performed in a fashion allowing a more favorable ratio of chelator to virus during exposure as well as the subsequent elimination of major amounts of chelating agents before assaying for RT activity, i.e., sedimentation of viruses through a solution containing the agent under study. Results are expressed as lytic activity LA as defined in Materials and Methods.

This index reflects the ability of a given agent to bring about a partial or complete disintegration of virus particles. Partially disintegrated particles, although to a variable extent damaged by exposure to chelator, remain sedimentable but exhibit RT activity as seein in aliquots (c) treated with agent but not with detergent.

On the other hand, the proportion of virus particles completely disassembled during exposure may be obtained by the difference of RT activities appearing in aliquots (b) and (d) treated without or with agent followed by disruption of the remaining virus with detergent.

To give an example with RLV exposed in aliquots (c) and (d) to 1 mmol/l ETA: the four viral aliquots displayed RT activities of (a) 1.1, (b) 38.0, (c) 10.4, (d) 32.7 dis/min (each x 10 to the third), respectively, yielding an LA value of 40. It appeared, however, not meaningful to discriminate between partial and complete disintegration and the LA value included by definition both events was therefore used. Fig. 1 (not shown) depicts the action of EDTA and EGTA on various retroviruses. These include mammalian type C viruses (RLV, SSV), primate type D viruses (MPMV, SMRV, PMFV) and BLV. Both chelating agents exert in millimolar concentrations a pronounced lytic activity upon most of the viruses tested so far.

Mammalian type C viruses seem to be somewhat less susceptible than the other viruses. The avian type C virus AMV, however, was exceptional in that it did respond to neither EDTA or EGTA. The reason for that was not investigated but may be related to some peculiarities of the envelopes of the avian type C viruses as compared to their mammalian counterparts (23). Since RLV just as AMV was obtained from the plasma of leukemic animals and there was no difference in the susceptibility of RLV irrespective of originating from infected animals or tissue cultures, it appears to be unlikely that unresponsiveness of AMV is due to certain conditions of extracellular viral maturation.

Concentration Dependence of Disintegrating Activity of EDTA and EGTA In initial experiments it was noted that retroviruses respond to chelating agents in a dose dependant manner. Fig. 2 (not shown) illustrates that PMFV, studied in greater detail, is susceptible to chelators over a wide range of concentrations. Complete disintegration, however, was reached with neither EDTA nor EGTA even in high concentrations up to 50 mmol/l.

This may indicate that only a certain fraction of particles present in a given virus population is sensitive to these agent possible owing to variations in age, stage of maturity, or other factors. Such variables are known to influence the response of retroviruses to detergents (43). Which Ion Is Involved in Disintegration A major question arising from the experiments described so far is the nature of the cation complexed by the chelating agents and probably somehow responsible for the integrity of viral particles. Effectiveness of EGTA with its high binding affinity for Ca++ (stability constant log K=10.9) and relatively low affinity for Mg++ (log K=5.9) (3) clearly supports a role of calcium in virus integrity.

However, the ability of EGTA to produce disintegration even in low concentrations may suggest that magnesium is also involved in maintaining the integrity of retroviruses, since the EDTA has binding affinities to both Ca++ (log K = 10.7) and Mg++ (log K = 8.9). The low amount of virus available for analysis did not yet allow an identification of the respective cation(s) by means of chemical or physicochemical methods. The possibility that EDTA and EGTA chelate different cations in retroviral membranes led us to examine a possible synergistic action of both agents on retroviruses.

Thus far, however, no increase in LA values has been observed after exposure of viruses to equimolar mixtures of both chelators. To further substantiate the involvement of one of the ions under consideration, experiments were performed to ascertain whether the addition of divalent cations could prevent the action of EDTA or EGTA (not shown). As already reported for PMFV (32) and now confirmed with other viruses, both MgCl2 and CaCl2 prevented disintegration of retroviruses when simultaneously added with the chelating agent.

However, addition of these cations at a later time did not cancel the effect produced by EDTA or EGTA. These results corroborate the assumption that both Ca++ and Mg++ ions are associated with retroviruses. Moreover, they exclude the possibility of involvement of such heavy metal ions binding more strongly to EGTA than Ca++, because in that case addition of CaCL2 or MgCl2 would not have prevented disintegration.

Effect of EDTA and EGTA on Infectivity of RLV That chelating agents indeed adversely affect retroviral membranes was independently demonstrated in another set of experiments. RLV, contained in cell-free spleen homogenates, was incubated in vitro with EDTA or EGTA and then injected into mice for analysis of leukemogenic capacity.

As compared to saline incubated virus in the controls, this treatment led to a marked inhibition of splenomegaly as well as to a doubling of mean survival time of infected animals (Table 2 not shown). Therefore, disintegration of virus particles as biochemically measured is paralleled by an equivalent loss of infectivity. The remaining virus, however, was still able to cause leukemia being diagnosed (courtesy of Prof. F. Fey) at the time of death of animals. Nevertheless, antiviral activity of chelating agents was also reflected in the pronounced depression of particle bound RT activity in the plasma of mice inoculated with treated virus.

During the course of development of leukemias, there was a considerable delay in reaching comparable levels of RT activity in blood of treated as against control mice. Susceptibility of BLV to Different Beta Blockers The hypothesis that Ca++ may be associated with retroviruses was further tested in animals with beta receptor blocking drugs.

Propranolol, a nonselective beta blocker used in medical practice, has been shown to be able to interact with membranes under concomitant Ca++ displacemant (2). It also disrupts membranes of type C and type D retroviruses (41). Contrary to propranolol, some of its congeners cardioselective beta blockers like practolol, sotalol and atenolol lacking the hydrophobicity of propranolol, do not essentially influence membrane phospholipids and membrane boud Ca++ (2,17,24).

For that reason it appeared of interest to examine the susceptibility of a retroviruses to these drugs. BLV was chosen because it was not included in our earlier studies. Table 3 (not shown) shows that exposure to propranolol in vitro clearly disintegrates BLV, as previously demonstrated with other retroviruses. Exposure to one of the propranolol congeners however produces only a small, if any, disintegration of BLV.

These results may thus provide additional evidence for calcium as the ion to take into consideration. Lytic Action of Trifluoperazine on Retroviruses The effect of trifluoperazine (TFP) on retroviruses ws investigated because

(i) other phenothiazines have been found to exert a lytic effect on retroviruses in vitro (41),

(ii) drugs of this type are known to produce, along with a variety of other effects on biological membranes, a displacement of Ca++ from membrane components (29) and

(iii) TFP is able to bind in a Ca++ dependant manner (18,19) highly effectively to calmodulin, a widespread regulatory protein (16), and is therefore widely considered as a specific probe for calmodulin. In view of these properties disintegrating activity of TFP on retroviruses could serve as an indicator both for the presence of Ca++ and for the identification of a putative Ca++ binding molecule in retroviral membranes. In fact, following exposure to TFP retroviruses of type C or type D as well as BLV displayed a release of RTactivity (table 4) [not shown].

The effect was again dose dependant. To favor a Ca++ specific binding of TFP to viral components, exposure was performed at pH 7.2 and not at pH 8.3 as usually, because pH values above 7.5 diminish the specificity of binding (36) .

Despite some variations with different viruses, TFP showed a similar disintegrating activity as various phenothiazines (41). Although AMV failed to respond to EDTA and EGTA, this virus was found to be susceptible to TFP, similarly as to other phenothiazines (41), too. From the results of this set of experiments it is tempting to conclude that retroviral membranes donot only contain Ca++ but possible also a Ca++ binding protein (7) which may be calmodulin like in sharing with this protein the property of responding to TFP.

Discussion In the present work designed to evaluate the action of the action of chelation agents on retroviruses in vitro we have mainly used a procedure sonsisting of centrifugation of intact virus particles through a solution of each respective agent and subsequent assay for RT to detect disintegration of the viral membrane.

The results show that these agents are capable of disintegrating all of the mammalian retroviruses tested. This finding was supported by experiments showing decreased infectivity of RLV after the virus had been treated with chelating agents. Principally, disintegration of retroviruses in vitro may occur either spontaneously or by treatment with membrane active agents. Spontaneous disintegration thought to be due simply to aging of particles is variable but usually low.

On the other hand, a variety of agents including detergents (21) , lipid solvents (21), and neurotropic drugs (41) as well as proteins such as human (37) or nonhuman primate complement (30) and melittin (12) cause a complete or nearly complete lysis of retroviruses. Complement mediated virolysis affects the P15(E) protein known to be embedded directly into the retroviral membrane (1).

Other interesting agents are the polyene antibiotics and membrane channel formers filipin (22) and nystatin (12) which induce some alterations in but nor disintegration of the membranes of retroviruses while retaining their infectivity.

This study revealed still another type of response with some dissociaton of membrane components that affects the infectivity of virus but does not necessarily result in complete destruction of viral particles because a variable proportion of them remains sedimentable even after treatment with chelators. Thus, retroviruses may exhibit a broad range of response to exogenous factors. However, among such factors, chelators like EGTA are rather exceptional in that they do not represent true membrane active agents, although several observations point to a role of Ca++ in membrane stability. (6).

There is increasing evidence for some association of Ca++ with viruses and a role of this ion in maintaining viral structure. The observation of calcium binding sites is nearly 20 plant viruses including tobacco mosaic virus, and also bioenergetic considerations, led DURHAM (10,11) to propose that Ca++ might generally control disassembly of such viruses. Other authors succeeded in disassociated of polyoma virus by chelation of Ca++ (4) and reassembly of infectious viral particles by subsequent addition of Ca++ (5). Exposure of rotavirus particles to calcium chelators resulted in an unmasking of internal RNA polymerase activity (9).

On the basis of these findings it is tempting to assume that association with Ca++ is a widespread property among viruses of different families. The viral components associated with Ca++ have not been identified. One possibility is that the attachment of Ca++ to phosphatidylserine (13) known to occur in the so far analyzed retroviral membranes (28). Distinctive features of model membranes have been attributed to interactions of Ca++ with membrane phospholipids and there is evidence that the viral membranes behave in this respect similarly as model membranes, e.g., in virus induced cell fusion processes (27). On the other hand, certain proteins could serve as receptors for Ca++ owing to their ability to bind Ca++ in a selective and reversible fashion.

The prototype of such Ca++ binding proteins is calmodulin, which, upon binding of Ca++, undergoes a confirmational change needed for its biological activity (16). In the presence of Ca++, calmodulin avidly binds phenothiazines (with TFP being the most effective one) and becomes thereafter biologically inactive (36). Propranolol is another antagonist of calmodulin (35).

Consequently the strong retrovirus disintegrating activity of TFP, other phenothiazines, and propranolol (41) may be considered as preliminary evidence for the occurrence of calmodulin like proteins in retroviral membranes, though it remains to be identified. During complex formation of Ca++ both with phospholipids (26) and proteins (39) there is some synergism with Mg++ and it is, therefore, well conceivable that both cations simultaneously occur in rteroviral membranes.

Whatever the mode of Ca++ binding to viral components is, and irrespective of whether Ca++ is accidentally or even specifically complexed to them, the occurance of Ca++ in retroviral membranes may have biological implication with regard to the assembly and disassemble of viral particles in and their budding from infected cells. Generally Ca++ has been found to influence a wide variety of functional properties of biological membranes.

Finally, identification of Ca++ binding viral components may eventually prove useful in the search for new and effective retroviral agents. The presently limited success of virus chemotherapy with chelating agents (20) might be generally augmented by considering such components as drug targets, too. Our recent demonstration that haloperidol, a colmodulin binding butyrophenone (19), exerts an antiviral effect on Raucher murine leukemia virus in vivo (42), may support the feasibility of this approach.

more information at: Chelation

more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Bio-Chelat: Chelation Therapy Clinical Trial - US Study

Clinical Investigation of Bio-Chelat(TM) Chelation Therapy

Results of the Bio-Chelat(TM) Clinical Study with Doctors Data Inc.

The clinical study was conducted over a 14 day-period, starting January 6, 2002 and ending April 18, 2002. Only 11 of the 20 participants fully complied with the experimental protocol and completed the Bio-Chelat(TM) clinical study.

Due to the limited number of observations, David Quig Ph.D. of Doctors Data, was unable to perform the appropriate statistical analysis required for a legitimate evaluation of the trial results. The German Bio-Chelat(TM) study utilized blood, while the U.S. study made use of urine and fecal analysis.

In retrospect, and on close review of all data, Target Your Health, Inc. noticeably sees, that the test design was not fully appropriate because of the specific pharmacokinetics of Bio-Chelat(TM). The decision was therefore made to revise the experimental design study, monitor patient compliance more closely, and conduct another clinical trial utilizing blood in conjunction with Doctors Data.

Nevertheless Dr. David Quig of Doctors Data stated: "Although the U.S. study sample was insufficient, it appears that the preliminary data that was collected show that Bio-Chelat(TM), chelation therapy, brought about elimination of heavy metals of the participants."
To understand how the Bio-Chelat(TM) solution differs and works in comparison to other chelators i.e. (DMPS, DMSA,EDTA, etc), following is a summary description of the pharmacokinetics.

Clinic-Pharmacological Data of Bio-Chelat(TM).
Pharmacokinetics: Bio-Chelat(TM) contains a complex-forming agent (EDTA) and an oxidative catalyst. The oxidative catalyst has the following function:1. To oxidize the SH-groups into SO3 2- groups or SH-ions into sulfate. SH-groups or SH-ions are ubiquitous in the GI tract and form very strong bonds with heavy metals.

The bonds of the newly formed SO32-groups or sulfate groups are reduced, thus allowing this very low concentrated (homeopathic) dosage of EDTA to easily bind with the heavy metal ions. In an acidic environment (i.e. stomach, intestines etc), EDTA forms a high complex bond with mercury, cadmium and lead. Because of this, heavy metals coming from the food, teeth roots, bile etc. are chelated and excreted with the feces.

By decreasing the uptake of mercury ions into the blood stream and creating a high electric-magnetic gradient in the GI-tract, new heavy metal ions are pulled from the body into the blood stream and stomach/intestine and excreted (Law of Isotonicity).

One example: When taking Bio-Chelat(TM), (DL) the urine clearly showed an increased amount of Cadmium and Nickel. On the other hand, fecal excretion of Cadmium, Mercury, Lead decreased.Analysis: When Bio-Chelat(TM) is absorbed into the GI tract, heavy metals are chelated and excreted with the feces.

This "clean-up" of the GI tract can last between 24 hours to 1 week and depends on the patient. During this period higher values of excreted heavy metals can be seen. Once the "clean-up" is completed, a lower concentration of heavy metals is then found in the feces. Lesser heavy metals are now absorbed into the blood, creating an imbalance between the blood and the deposits, which then will pull new heavy metals into the blood stream from the deposits, which are then excreted via the urine and feces.

As formulated by Dr. Leman in the German study:
Bio-Chelat((TM), chelation therapy, will indirectly intensify the body's physiologic elimination mechanism of heavy metals. When comparing values prior to Bio-Chelat(TM) intake, due to the minimization of heavy metals into the blood (blood doesn't receive anymore metals from the GI-tract), the balance between heavy metal depots and blood is disturbed, and heavy metals spill over (are pulled) into the blood, and are then discarded via the kidneys and intestines.

An increase in the heavy metal concentration of the urine and feces should not be measurable, because even the blood level of heavy metals should now be inferior compared to the pre-therapeutic level. For long-term therapy, this physiological mechanism can be utilized to eliminate heavy metals.

Final Conclusion
The therapeutic value of Bio-Chelat(TM) in the context of chelators currently on the market is seen as follows:

a) Chelators work relatively fast, but they are also very strong with a relative high washout of important trace elements and a high degree of specific side effects.

b) Bio-Chelat(TM), chelation therapy, works much gentler and is easier as most common chelators.

c) Bio-Chelat(TM) is not suitable for acute care of heavy metal toxicity or a very high toxic ion loads.

d) Bio-Chelat(TM) has its greatest value as a middle and long-term therapy for chronic heavy metal toxicity and especially in preventing heavy metal toxicity through the today's overall heavy metal exposition. For this it is the optimal product.

e) The side effects of Bio-Chelat(TM) are minimal when compared to the overall effect. Those side effects can be totally eliminated through a modification of intake and dose. No associated risks are connected with the use of Bio-Chelat(TM).
Because of this, Bio-Chelat(TM), chelation therapy, is excellent in view of the numerous patients carrying a chronic heavy metal ion load.
It is a necessary solution.

more info at:
http://www.dreddyclinic.com/integrated_med/chelation.htm

Bio-Chelat: Chelation Clinical Trial - German Study

Clinical Investigation of Bio-Chelat(TM)
This investigation was done according to the recommendation of 83/571 EWG, Part IV, dated 11/28/1983 (EG#L332).

Planning, methodology, completion, evaluation and documentation went according to the appropriate principles for clinical drug testing, dated 12/09/1987 (Banz. Page 16-617).
Clinic-Pharmacological Data

1. Pharmacological Dynamics
For this clinical evaluation, a standard dose of 3x20 drops was used and well tolerated by most patients. We recommend taking the chelation solution before meals. With associated dryness of the mouth, follow the solution with water. We also recommended decreasing the dosage to 3x15 or a minimum of 3x10 or 2x15 drops per day when a decrease of saliva was noted. Dryness of the mouth was rarely experienced with the reduced dose and whenever it was an issue, most symptoms disappeared 3-4 weeks after taking the Bio-Chelat(TM).

There was an obvious connection between the release of mercury ions from amalgam fillings using Bio-Chelat(TM) Chelation therapy, and the subsequent depressive effect of this release on the salivary glands. It turns out that the amount of liquid taken by the participant is of particular importance. Participants were instructed to drink a minimum of 2 liters of water per day to ensure adequate mercury excretion by the kidneys. However, not all participants followed the recommendation. Those participants, who drank less increasingly complained of mouth dryness.

The time-relationship-effect concludes that Bio-Chelat(TM) is fast absorbed and its' maximum effect occurs during the first 1-3 hours when the most excretion takes place. Because of this, it is necessary and indicated to take the solution 3 times per day. The increased digestibility after a few weeks concludes that either a tolerance occurs or that the mercury elimination is sufficiently advanced.

To see the chelation effect on the body, blood panels must be assessed (especially calcium, magnesium, zinc as well as heavy metals), to check for toxic consequences within the kidneys and to determine mercury excretion. Also, liver panels to determine metabolic performance and evaluate possible hepatotoxic action of Bio-Chelat(TM). According to the published data, there were no negative responses when observing blood count; life essential mineral concentration also did not change. Only zinc was significantly decreased, and therefore, zinc supplementation should be considered whenever necessary. Thrombocyte count also decreased slightly, while leucocytes increased minimally. On the other hand, mercury levels decreased, as well as other heavy metal ions (lead, cadmium), which is seen as a positive finding.

Specific kidney parameters showed no negative consequences to the kidneys. In regards to the liver panel, we recognized a small insignificant increase of gamma-GT-values. The observed changes in LDH and GOT are not significant. This is most likely because of the increased demand placed on this organ with the excretion of toxic metal ions.

2. Pharmacokinetics and Bio-availability

A pharmacological determination of absorption, distribution, change, and excretion of Bio-Chelat(TM) or its by-products did not occur. This is unusual with homeopathic diluted agents. The optimum dose is a compromise between desired effect on one hand and side effects on the other. Here it was a minimal dose of 3x10 drops and an optimal dose of 3x20 drops. The maximal dose should not be strived for.

3. Effect with continued use
The therapeutic goal of mercury elimination can39;t be achieved in a short time because mercury is either deposited or bound to various organs. A fast mobilization using chelation therapy can bring considerable side effects.

Because of this it is normal and appropriate to take Bio-Chelat(TM) over at least a 3-month time span. Longer time periods are only indicated when, for example, there are mercury extractions, removal of amalgam fillings or new fillings are being placed.

We know that Bio-Chelat(TM) is an excellent solution as long as the mercury concentration in the serum, urine or sputum continues to be high, and there are occasionally new chemical exposures that would make it useful to continue taking the solution daily.

4. Side effects
None are known. In this study, no patient gave such an indication, although it should be mentioned that all participants had a naturopathic medical orientation and do not take pharmaceuticals.

Clinical Therapeutic Data
The results of this study was based on 74 participants and was documented statistically, including side effects. Each patient was questioned about side effects of the chelation therapy during the exit interview. Questions centered on how the solution was taken, as well as how they felt during the trial and how they tolerated the solution. This information is given whenever known.

· All users were clients from the HG Homeopathic Clinic, which is the practices of Drs. Pieper/Bender, Hautzel, Rebien and Schneider, as well as from the dental practices of Drs. Obermayer and Obreschko.

· Testing Method: More than 60 participants were examined, all having mercury-amalgam-fillings; their mercury and heavy metal load was checked and the effects of the Bio-Chelat(TM) on this heavy metal burden.

· Hypothesis: Will Bio-Chelat(TM) reduce this load significantly after taking it for 3 months? For verification and documentation, blood, urine, and sputum examination was used, as demonstrated on the enclosed table. Absorption spectrometry, done at the Diagnostic Center for Mineral Analysis and Spectroscopy (Lowensteinst. 9, Michelrieth), was the specific method used to measure these metals within the serum.

· The company Hormonology produced Bio-Chelat(TM) (a liquid solution enriched with minerals in addition to 100 ml of oxygen). The standard dose recommended by the manufacturing company was 3 x 20 drops/day. It was recommended to take a teaspoon of Bio-Chelat(TM) before meals, followed with water. The dose was modified when necessary for the participant.
· The test was done over a 3-month period. Because it took 3 months to find appropriate test participants, the complete study lasted from January 1, 1995 until July 31, 1995.

· No additional therapies were done or recommended.
· The desired effect was a decrease of the serum mercury, lead, cadmium, and palladium concentrations upon completion of the program.
· Undesirable effects were any associated dryness of the mouth, stomach problems and occasional nausea. These were present in a few cases and Bio-Chelat(TM) was discontinued. Those problems generally decreased after 3-4 weeks. Nevertheless, in a few cases an adjustment of the dosage was necessary. Side effects were generally only noted for 1-2 hours and did not cause any further problems.
· The therapeutic value of the Bio-Chelat(TM) in the context of other chelators that are currently on the market is seen as follows:
Chelators work relatively fast, but they are also very strong with a relative high washout of important trace elements and a high degree of specific side effects.

Bio-Chelat(TM) works much gentler than with most common chelation therapies.

Although during the treatment a significant decrease of the body's heavy metal ion load was seen, this is accomplished without greatly disturbing the mineral and trace element relationships. The reduction of zinc should be looked at with caution and may easily be corrected throughout the treatment.

A small increase in the liver panel is, as mentioned earlier, partly due to the increased load on the liver while eliminating heavy metal ions. In a few isolated cases, it was observed that those values completely approached normal levels within a few days or weeks, particularly when liver supportive and excreting therapies were simultaneously administered. All liver panel values were normal upon completion of the Bio-Chelat(TM) study.

Should a patient have liver damage, and have for example an increased transaminase value, Bio-Chelat(TM) should be given very carefully while evaluating the risks.

Bio-Chelat(TM) is not suitable for acute mercury poisoning or very high new toxic ion loads.Bio-Chelat(TM) has its greatest value as a middle and long-term therapy for sub-acute or chronic mercury toxicity. For this it is the optimal product.

The side effects of Bio-Chelat(TM) are minimal when compared to the overall effect. Those side effects can be totally eliminated through a modification of intake and dose. No associated risks are connected with the use of Bio-Chelat(TM). After discontinuance of the Bio-Chelat(TM) any effects disappear within hours.

Because of this, Bio-Chelat(TM) is an excellent chelation therapy that will fill today's market niche, in view of the numerous patients carrying a chronic toxic mercury and heavy metal ion load. It is a necessary solution for that particular market.

more information at: Chelation

more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Benefits of EDTA Chelation Therapy in Arteriosclerosis

Journal of Advancement in MedicineVolume 6, Number 3, Fall 1993
Benefits of EDTA Chelation Therapy in Arteriosclerosis:A Retrospective Study of 470 Patients. Hancke, Md, and K. Flytlie, MD

ABSTRACT: In a retrospective study we report results of EDTA chelation in 470 patients, using a number of parameters, most of them objective. Although the patients acted as their own controls, we observed improvements of 80 to 91%, depending upon the measurements used.

Of 92 patients referred for surgical intervention, only 10 required ultimate surgery after or during their chelation therapy, thus saving an estimated 3 million dollars of insurance money.

Our experience covers a period of 6 years and we saw no severe side-effects or casualties arising from the treatment. We conclude that EDTA chelation therapy is safe, effective and cost-saving.
Introduction
Intravenous administration of ethylene diamine tetraacetic acid (EDTA) has been used from the beginning of the 1950s by an increasing number of physicians throughout the world for the treatment of arteriosclerosis. In the last few years, there has been increasing criticism of surgical intervention in this disease, since it fails to prolong life, and is a temporary solution in treating a generalized, chronic condition (1).

In addition, surgery damages vital tissue by means of reperfusion-released free-radical bursts (2,3). Evidence for effectiveness of EDTA chelation therapy is cumulative over many years (4-9), and the recent association of iron in the etiology of cardiovascular disease (10) makes the technique worthy of complete acceptance today.

It has been proved effective in a number of clinical trials (11-16). The impact of oxidative processes on age-related illness is a relatively new science, which began in the late fifties. The impact of oxygen derived free radicals on the occurrence of reperfusion damage is well documented (2-5,8,9). That the method is ignored here in Denmark may be due to lack of understanding of the importance of these processes.

Another possible explanation may be the harsh attitude of the Danish vascular surgeons from the first introduction of chelation therapy in Denmark in 1987. A study of 153 patients with claudication was published in three different journals in 1991 and 1992 (17-19). This study, which is seriously defective, has been publicly opposed (20,21). It is the only existing study that did not show a significant benefit from EDTA therapy. The results were better in the treatment group, but the effect was reportedly not statistically significant.

Claus Hancke M.D. received his medical education at the University of Copenhagen. He is general practice and is president of the Danish Chelation Doctors. He is an ABCT diplomate.
Knut Flytlie M.D. received his medical education at the University of Gutenberg, Germany. He is in general practice and operates a clinic for Preventive Medicine and Chelation. He is an ABCT diplomate.

Address correspondence to Claus Kancke, M.D., Lyngby Hovedgade 17.1. DK – 2800 – LYNGBY, Denmark.© 1993 Human Sciences Press, Inc.

MATERIALS and METHODS
This study included 470 patients with claudication and/or angina pectoris, who received at least 15 women and 311 men. Of these, 206 were older than 69 years, 92 between 65 and 69, 90 between 60 and 64, and 82 under 60 years. Diagnosis was verified by systolic ankle-arm blood pressure index (Doppler technique), and by stress test on a treadmill. All were interviewed and examined by a physician before and after treatment.

METHOD
All patients were given I.V. infusions of 500 ml sterile water with Na2
EDTA, 50 mg/Kg (Maximum 3 grams) and the infusion included Vitamin C, sodium bicarbonate and magnesium as prescribed in the protocol of the American College for Advancement in Medicine (ACAM) (22).

In addition, the patients were provided with an oral high dose vitamin/mineral supplementation without iron and copper, 6 tablets a day. Before treatment, a determination was made of blood hemoglobin, erythrocyte sedimentation rate, fasting blood glucose, creatinine, creatinine clearance, total and HDL cholesterol, triglycerides, leucocytes, uric acid, sodium and potassium.
All patients were counseled by both verbal and written communication on the importance of physical exercise, proper nutrition and omitting tobacco.

Treatments were administered on an out-patient basis and continued until the patients had a stable clinical situation. This usually required 30 treatments of 3-4 hours duration over a period of 3-4 months. Final assessment was made on completion of treatment and again 2 months later when complete physical examination was repeated.

Patient with claudication had their ankle-arm index, walking distance, foot temperature, pain at rest, skin color of feet and healing of wounds assessed and registered. Subjective judgement of resting pain was rated on a scale from 1-3. Patients with angina pectoris had their working capacity measured on a treadmill, and ST depression by electrocardiogram. Any arrhythmias, blood pressure, body weight and kidney function were noted.

The subjective judgement of results was rated on a scale from 1 to 3 with regard to the number of attacks of angina pectoris and consumption of nitroglycerin (1: worse, 2: unchanged = 10%, and 3: improved). Medications, general state of health, energy level, smoking habits, hearing, visual sense and presence or absence of “dizziness” were recorded.

RESULTS
Results of the 470 patients completing treatment are shown in Tables 1 through 5. Table 1 shows the sex distribution and results in 265 patients with myocardial ischemia. Of these, 101 over the ages of 69 were improved, 6 were the same and one was worse. Of those between 60 and 69 years, 93 were better, 9, unchanged and 1 was worse. Below the age of 60, 47 were better, 7 unchanged and none were worse. The two patients who were worse were the only ones with angina pectoris who received less than 31 treatments.

In the group with claudification, including 262 patients, we found an improvement in 82%, distributed according to age and sex as shown in Table 2. Table 3 shows the ankle/arm ratios which were improved in 82%. Walking distance, which includes both claudification and myocardial ischemia patients, was improved in 87% of the patients.

Figure 1 shows the numbers of patients threatened with amputation or coronary by-pass surgery before and after EDTA chelation therapy. Several of the patients in the claudification group started treatment very late in the course of the illness. Of 44 who had problems with wound healing, 31 improved, 11 were unchanged and 2 became worse. Of 137 who complained of cold feet, 110 improved, 27 were unchanged and none became worse (Table 3)

In the group with angina pectoris, many were so severely disabled that they had been refused bypass surgery, and no other medical treatment was offered. As shown in Table 4, of 253 patients with electrocardiographic S-T depression, 175 showed improvement, 74 were unchanged and 4 had increased S-T depression. The average blood pressure decreased in 109 patients, 37 were unchanged and one had a higher blood pressure. Working capacity was assessed in both myocardial ischemia and claudication patients. This was measured in Joules by computerized ergometry. Of 318 patients undergoing this study, 271 showed improvement (85%).

TABLE I
This Shows Results of Treatment of 265 Patients with Myocardial Ischemia. Of 65 Patients Referred for Bypass Surgery, 58 did not Require if After Their Course of Chelation.
Worse
Same
Better
% Improved
Sex of Patient:FemaleMale
-2
715
69172
91%90%
Age-groups of patients:Over 69 years65-69 years60-64 yearsUnder 60 years
1-1-
6457
101484547
93%92%86%87%
Referred to:Before ChelationBy-PassDilatationAfter ChelationBy-PassDilatation
1-1-
7151
57212
85%67%0%67%
No. of Treatments:Less than 3131-3536-4041-50More than 50
2----
1631-2
1444020307
88%93%95%100%78%
Of 207 patients using nitroglycerine, 189 reduced their consumption. Most of them were able to discontinue its use altogether. However, 16 continued with the same dose as before and 2 had to increase their dose.

No morbidity or serious side effects directly due to the treatment were reported in the clinics from 1987 to 1993. Table 5 shows the benefits in other parameters as well as it shows difficulty in handling the problems of smoking and excess body weight. Fortunately, only 147 of the 470 were smokers initially and 86 of them continued to smoke during the treatment
TABLE 2
This Shows Results of Treatment of 262 Patients with Intermittent Claudication. Of the Patients Referred for Amputation, 24 of 27 Legs were Spared Following Their Course.
Worse
Same
Better
% Improved
Sex of Patient:FemaleMale
21
1824
76140
77%84%
Age-groups of patients:Over 69 years65-69 years60-64 yearsUnder 60 years
21--
21984
105443929
80%80%83%88%
Referred to:Before ChelationBy-PassDilatationAfter ChelationBy-PassDilatation
---1
221-
72522
78%92%67%0%
No. of Treatments:Less than 3131-3536-4041-50More than 50
3----
384---
12533252410
73%89%100%100%100%
FIGURE 1
This provides a graphic representation of the data shown in Tables 1 and 2. The first column represents the number of patients referred for surgery. The second column shows the number that required surgery after completing chelation.
TABLE 3
This is Primarily to Show Results in the 262 Patients with Intermittent Claudication. However, "Walking Distance" Includes some Patients with Angina
Worse
Same
Better
% Improved
Ankle/Arm BP Ratios
3
42
217
82%
Wound-healing
2
11
31
66%
Rest-pain
1
15
87
83%
Foot-temperature
-
27
110
80%
Skincolour of feet
1
19
64
75%
Walking Distance
3
33
72
87%
FIGURE 2
Claudication. This is a graphic presentation of the same data as revealed in Table 3.

TABLE 4
Working Capacity, Tested by Computerized Ergometry, Refers to both Patients with Angina and Intermittent Claudication who were Tested by this Method. The Rest of the Table Refers to Those with Coronary Heart Disease.
Worse
Same
Better
% Improved
ST-Depression
4
74
175
69%
Arrhythmia
-
24
39
62%
Blood Pressure (mean)
1
37
109
73%
Angina Pectoris
2
22
241
91%
Nitroglycerin Demand
2
16
189
91%
Working Capacity (objective)
4
43
271
85%
FIGURE 3
Myocardial. This is a graphic presentation of the same data as revealed in Table 4.
TABLE 5
This Shows the Results of Evaluating Subjective Symptomatology in the Entire Group of 470 Patients. Renal Function was Judged by Creatinine Clearance.
Worse
Same
Better
% Improved
General Wellbeing
4
41
371
88%
Working Capacity (subjective)
6
42
363
87%
Energy/Initiative
7
38
319
86%
Vertigo
4
13
71
76%
Memory
2
19
48
67%
Medicine Consumption
5
98
212
66%
Hearing
2
60
121
65%
Visual Sense
5
22
54
60%
Renal Function
8
83
100
48%
Smoking Habit
2
84
61
40%
Overweight
13
107
36
15%
Subjective improvement in coldness of feet, increased energy and work capacity, together with striking improvement in general condition were noted by most patients. Several of the male patients reported improved sexual potency, improved sight and hearing, and symptoms like migraine and tinnitus disappeared as an unexpected bonus for many patients.

Although a placebo effect could not be ruled out, of course, the degree of improvement was remarkable and exceeds our previous experience with similar patients. Of 65 patients who referred for coronary by-pass surgery, 58 did not require it after chelation therapy. Of 27 patients awaiting amputation as the only surgical offer of treatment, 24 avoided surgery.

Discussion
In our view, the beneficial results were far excess of the 10-15% improvement that is usually seen in the placebo group of a controlled study. Some patients with claudication who were unable to walk more than 100 feet could walk painlessly for 2 miles or ride several miles on a bicycle after their treatment.

We found convincing evidence that EDTA infusion therapy is effective in treating arteriosclerosis. Our results are identical with those of other similar studies (12-16). Although the study registration was done in two sections, one in March 1991, and one in April 1993, the results are the same. It is evident that results are reproducible from patient to patient, from clinic to clinic and internationally.

Such results have led to a worldwide increase in interest in chelation therapy in medical circles familiar with the theoretical principles of oxygen derived free radical pathology. This interest has resulted in an increased scientific effort by a number of investigators (4,12-16,23-26)
On the basis of such well published data, it seems to us that it is unethical to wait for a randomized, double blind, cross-over study to approve EDTA chelation for the treatment of arteriosclerosis, though we admit that such a FDA approved study would set the seal on this therapy if it were to be as successful as we believe it would be, based on our results and those already published.

Since there is massive evidence that the spontaneous development of arteriosclerosis is the number one killer disease in the Western World, there is every reason to hasten to increase our efforts to bring this important therapy into mainstream medicine as soon as possible.

Conclusion
In spite of the weakness and possibility of bias in a retrospective study without a control group, the historical record for treatment of this disease is poor. We find it difficult not to conclude that EDTA chelation therapy is a safe, effective and cost-saving method of improving angina pectoris and intermittent claudication. We urge a massive and concerted effort to study the method further.

Acknowledgement
We wish to express our gratitude for statistical support from A&F Research, Denmark.
References
1. Graboya T B, Headly A, Lown B, et al. Results of a second opinion program for coronary artery bypass graft surgery. JAMA 1987;258:1611-1614
2. Svendsen J H, Host N B, Haunso S. Reperfusionsakade i myocardiet - betydningen of oxygen-deriverede frie radikaler. Ugeskr laeger 1991;153/24:1717-1720
3. Grech J. Dodd N J F, Bellamy C M, et al. Free radical generation during angioplasty reperfusion for acute myocardial infarction. Lancet 1993;341:990-991.
4. Diehm C. Wonder remedy chelation - claims and actuality. Zeitschrift der Deutschen Herzstiflung 1986;10:11-15
5. Gutteridge J. Ferro-salt promoted damage to deoxyribose and benzoate. The increased effectiveness of hydroxyl radical scavengers in the presence of EDTA. Biochem J 1987;243:709-714.
6. Lamb DJ, Leake D S. The effect of EDTA on the oxidation of low density lipoproptein. Atherosclerosis 1992;94:35-42.
7. Saffer A Chelation therapy for arteriosclerosis. JAMA 1975;233:1205-1207.
8. Peng C F, Kane J J, Murphy M L, et al. Abnormal mitochondrial oxidative phosphorylation of ischemic myocardium reversed by Ca2-chelation agents. J. Molecular Cellular Cardiol 1977;9:897-908.
9. Zylke J. Studying oxygen's life-and-death roles. JAMA 1988;259;960-965.
10. Salonen J T; Nyyaonen K. Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation 1992;86:8-3-811.
11. Cranton E M, Frackelton J P. Free radical pathology in age-associated disease: treatment with EDTA chelation, nutrition and anti-oxidants. J Holist Med 1984; 6:6-37.
12. Olszewer E. Carter J P. EDTA chelation therapy in chronic degenerative disease. Med Hypoth 1988;27:41-49
13. Kaman R L, Rudolph C J, McDonagh E W, Walker E W, Walker F M, Effect of EDTA chelation therapy on aortic calcium in rabbits on atherogenic diets; Quantitative and historichemical studies. J Adv Med 1990:3:13-21.
14. Rudolph C J, McDonaugh E W, Barber RK. A nonsurgical approach to obstructive carotid stenosis using EDTA chelation, J Adv Med 1991;4:157-168.
15. Olszewer E. Sabbag F C, Carter J P. A pilot double blind study of sodium-magnesium EDITA in peripheral vascular disease. J National Med Assoc 1990;82:173-177.
16. Olszewer E. Carter J P. EDTA chelation therapy: a retrospective study of 2,870 patients. J Adv Med 1989;2:197-211.
17. Guldager B. Jelnes R. Jorgensen S K, et al. EDTA-treatment of intermittent claudication: a double blind, placebo controlled study. J Int Med 1992;231: 261-267.
18. Guldager B, Jelnes R. Jorgensen S J, et al. EDTA-versus placebo behandling of claudication intermittens. Ugeskr Laeger 1992;154/23:1618-1621.
19. Sloth Nielsen J. Guldager B. Mouritzeen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg 1991;162:122-125.
20. Cranton E M, Frackelton J P. Negative study of EDTA chelation biased. Townsend Letter for Doctors 1992: July:604-605.
21. Hancke C, Flytlie K. EDTA manipuleret. Ugeskr Laaeger; 1992;154:2213-2215.
22. Cranton E M. Protocol of the AMerican College of Advancement in Medicine for the safe and effective administration of EDTA chelation therapy. Cranton E M, ed: In: A textbook on EDTA chelation therapy. J Adv Med 1989;2:269-305.
23. Casdroph H R. EDTA chelation therapy II: efficacy in arteriosclerotic heart disease. J Holist Med 1981;3:53-59
24. Casdorph H R, Farr C H. EDTA chelation therapy III: treatment of peripheral arterial occlusion, an alternative to amputation, J Holist Med 1983;5:3-15.
26. McDonagh E W, Rudolph C J. Cheraskin E. An oculo-cerebro-vasculometric analysis of the improvement in arterial stenosis following EDTA chelation. J Holist Med 1982;421-423

more information at: Chelation

An Oculocerebrovasculometric Analysis

An Oculocerebrovasculometric Analysis of the improvement in Arterial Stenosis following EDTA Chelation Therapy
E.W. McDonagh, DO, FACGPC.J. Rudolph, DO, PhDE. Cheraskin, MD, DMD

ABSTRACT: Fifty-seven patients were evaluated objectively for cerebral vascular arterial occlusion before and after an average of 28 intravenous infusions of disodium ethylene diamine tetraacetic acid. Measurements of arterial occlusion were made with the relatively simple, noninvasive oculocerebrovasculometric analysis.


Cerebrovascular arterial occlusion diminished by an average of 18% (from a mean of 28% to a mean of 10%) following therapy (P<0.001). href="http://www.dreddyclinic.com/integrated_med/chelation.htm">EDTA chelation therapy showed objective improvements in cerebrovascular blood flow.


Since C. Miller spelled out the clinical syndrome of carotid occlusive disease in 1951,
1 there have been increasing efforts to develop non-invasive tests for diagnosis of common and internal carotid lesions. The plethora of diagnostic procedures testifies to the difficulty in arriving at a fully satisfactory single technique.
2 This report, as far as we can ascertain, is the first attempt to examine the effect of intravenous disodium ethylene tetraacetic acid (EDTA) therapy plus multivitamin-trace mineral support upon arterial insufficiency (stenosis) utilizing one of the popular non-invasive techniques, namely oculocerebrovasculometry (OCVM).
Fifty-seven routine patients suffering with chronic degenerative disorders participated in this experiment in a private practice environment. Included were 34 males, age range from 23 to 83 years old with a mean and S.D. of 61.4 ± 11.2; and 23 females from 48 to 77 years old with a mean and S.D. of 60.2 ± 7.8.
At the initial examination, each patient underwent a detailed history, physical examination and comprehensive battery of biochemical tests. Each patient also underwent oculocerebrovasculometry (OCVM), a unique non-invasive tonometric system for the detection of arterial insufficiency (stenosis).
This technique was developed in cooperation with Maurice Langham, Ph.D., of the Wilmer Institute at Johns Hopkins University School of Medicine, 3,4 This non-invasive system simultaneously measures intraocular pressure and ocular pulse in both the undisturbed state and with the eye pressure increased to the ophthalmic arterial pressure.
The procedure measures the ophthalmic arterial pressure which, when compared to the brachial blood pressure, provides a reasonably accurate method of assessing carotid artery occlusive disease, cerebrovascular occlusive disorders, and ocular vascular pathology.5 Following the initial studies, each subject received a series of intravenous disodium EDTA infusion with a mean and S.D. of 28.4 ± 7.7 (ranging from 10 to 46).
Additionally, a multivitamin-trace mineral supplement (dosage approximately five to 10 times the RDA) was supplied. Upon completion of the EDTA and multivitamin-trace mineral series, each individual once again received a comprehensive history, physical examination, battery of biochemical tests, and oculocerebrovasculometry.
Five points deserve particular consideration. First, at the beginning, the mean percentage of arterial stenosis was 28% with a range from 3% to 74%. Following therapy, the average stenosis was 10% with a range from 0 to 54%. Hence, there was an overall statistically significant reduction in arterial occlusion of 18% (t=7.1931, P<0.001).>
Third, following treatment, at every temporal point, there is a significant mean reduction in stenosis of an order of 18% (t=5.3516, P<0.001), t="5.2566," t="1.6147,">
REFERENCES 1. Fisher M: Occlusion of the internal carotid artery. Arch Neurol Psychiatr 1951;65:346-377. 2. Ackerman RH: Cerebrovascular Survey Report. Non-invasive diagnosis of carotid disease. Washington, Joint Council Subcommittee on Cerebrovascular Disease. National Institute of Neurological and Communicative Disorders and Stroke and National Heart and Lung Institute. 1980 pp. 190-210. 3. Langham ME: A new procedure for the analysis of intraocular dynamics in human subjects. Exp Eye Res 1963;2:314-324. 4. Langham ME, To'mey KF: A clinical procedure for the measurement of the ocular pulse-pressure relationship and the ophthalmic arterial pressure. Exp Eye Res 1978;27:17-25. 5. To'mey KF, Langham ME: in press.
McDonagh Medical Center
2800-A Kendallwood Parkway
Gladstone, MO 64119
more information at: Chelation

Paratrex®

Paratrex®

$32.95
[ learn more ]

Add to Cart

Get Paratrex® and promote a natural cleansing of your system. Paratrex® helps create an environment hostile to invading organisms. Help flush your system clean!

Advanced Body Cleansing Kit

Advanced Body Cleansing Kit

$147.75
[ learn more ]

Add to Cart

Advanced Body Cleansing Kit with Livatrex™, Oxy-Powder®, Latero-Flora™ and two bottles of ParaTrex®.